Dow Jones

39,872.99

0.17%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

MESO

Mesoblast (MESO)

Mesoblast Limited

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MESO

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
29/04/2024	20:05	GlobeNewswire Inc.	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	NASDAQ:MESO	Mesoblast Limited
26/03/2024	08:25	AllPennyStocks.com	FDA Commentary Sends Biotech Soaring During Premarket Hours	NASDAQ:MESO	Mesoblast Limited
25/03/2024	21:34	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	NASDAQ:MESO	Mesoblast Limited
13/03/2024	18:30	GlobeNewswire Inc.	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	NASDAQ:MESO	Mesoblast Limited
10/03/2024	18:54	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	NASDAQ:MESO	Mesoblast Limited
28/02/2024	16:57	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
26/02/2024	06:00	GlobeNewswire Inc.	Mesoblast Financial Results and Corporate Update Webcast	NASDAQ:MESO	Mesoblast Limited
14/02/2024	18:46	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
31/01/2024	20:34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
30/01/2024	20:13	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
18/01/2024	18:28	Dow Jones News	Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment	NASDAQ:MESO	Mesoblast Limited
18/01/2024	17:36	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
04/01/2024	20:57	Edgar (US Regulatory)	Form F-6 POS - Post-effective amendments for immediately effective filing	NASDAQ:MESO	Mesoblast Limited
26/11/2023	17:56	GlobeNewswire Inc.	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
22/11/2023	12:35	AllPennyStocks.com	Biotech Shares Soar Following Major Announcement	NASDAQ:MESO	Mesoblast Limited
21/11/2023	17:32	GlobeNewswire Inc.	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	NASDAQ:MESO	Mesoblast Limited
30/10/2023	19:04	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	NASDAQ:MESO	Mesoblast Limited
26/09/2023	05:18	GlobeNewswire Inc.	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	NASDAQ:MESO	Mesoblast Limited
21/09/2023	02:30	GlobeNewswire Inc.	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval	NASDAQ:MESO	Mesoblast Limited
06/09/2023	05:42	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MESO	Mesoblast Limited
30/08/2023	18:07	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023	NASDAQ:MESO	Mesoblast Limited
04/08/2023	08:03	Dow Jones News	Mesoblast ADSs Plunge Premarket on Latest FDA Rejection	NASDAQ:MESO	Mesoblast Limited
03/08/2023	19:10	GlobeNewswire Inc.	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children	NASDAQ:MESO	Mesoblast Limited
30/07/2023	19:31	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023	NASDAQ:MESO	Mesoblast Limited
06/06/2023	07:46	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:MESO	Mesoblast Limited
04/06/2023	19:21	GlobeNewswire Inc.	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role	NASDAQ:MESO	Mesoblast Limited
30/05/2023	05:06	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:MESO	Mesoblast Limited
25/05/2023	18:28	GlobeNewswire Inc.	Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023	NASDAQ:MESO	Mesoblast Limited
27/04/2023	20:00	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report	NASDAQ:MESO	Mesoblast Limited
25/04/2023	19:47	GlobeNewswire Inc.	Mesoblast Completes Private Placement	NASDAQ:MESO	Mesoblast Limited